Skip to main navigation Skip to search Skip to main content

Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus

  • SUNY Buffalo
  • Medical University of Gdańsk
  • Tolerx, Inc.

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Abstract

Otelixizumab is an aglycosylated chimeric/humanized monoclonal antibody (mAb) directed to human CD3ε. This report describes population pharmacokinetics/ pharmacodynamic (PK/PD) modeling of serum otelixizumab concentrations, changes in CD4+ and CD8+ T-cell counts, and modulation and saturation of CD3/T-cell receptors (TCR) (determined by flow cytometry) after IV administration of otelixizumab in subjects with either type 1 diabetes or psoriasis. Otelixizumab PK were monoexponential with Michaelis-Menten elimination. Nonlinearity was manifested at high concentrations (Km = 0.968 μg/mL). Lymphocyte dynamics were captured by an indirect response model simplified to direct inhibition. In diabetic subjects, the otelixizumab serum concentration producing a 50% decrease in peripheral blood counts was 0.0187 μg/mL for CD4+ T cells and 0.0120 μ g/mL for CD8+ T cells. Corresponding values for psoriatic subjects were much lower: 0.000533 for CD4+ T cells and 0.000269 μg/mL for CD8+ T cells. Total (sum of unbound and otelixizumab-bound) CD3/TCR was approximately equal to unbound CD3/TCR, suggesting that there were few otelixizumab-(CD3/TCR) complexes at the T-cell surface. Down-modulation of CD3/TCR was described by direct inhibition. Otelixizumab concentrations producing 50% reduction in free CD3/TCR sites was similar for diabetes and psoriasis, 0.0144 and 0.0162 μg/mL. Integrated PK/ PD models were successfully applied to assess otelixizumab PK and diverse PD responses.

Original languageEnglish
Pages (from-to)494-506
Number of pages13
JournalJournal of Clinical Pharmacology
Volume50
Issue number5
DOIs
StatePublished - May 2010

Keywords

  • Otelixizumab
  • Pharmacodynamics
  • Population pharmacokinetics
  • Psoriasis
  • TRX4
  • Type 1 diabetes

Fingerprint

Dive into the research topics of 'Pharmacokinetics and pharmacodynamics of a chimeric/humanized anti-CD3 monoclonal antibody, otelixizumab (TRX4), in subjects with psoriasis and with type 1 diabetes mellitus'. Together they form a unique fingerprint.

Cite this